Hasan Syed, Dinh Kimberly, Lombardo Fred, Dawkins Fitzroy, Kark John
Division of Hematology/Oncology, Howard University Hospital, Washington, DC, USA.
J Natl Med Assoc. 2003 Aug;95(8):722-4.
Imatinib mesylate (STI 571, Gleevec) is a potent bcr-abl tyrosine kinase inhibitor. It also inhibits c-kit tyrosine kinase. Imatinib mesylate is active in the treatment of cronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). It is considered by some authorities to be the standard of care in newly diagnosed CML as well as patients in chronic phase who do not have a related match. C-kit and its ligand stem-cell factor regulate melanocyte development and survival. Hypopigmentation in patients receiving imatinib mesylate for CML has been reported recently. In this article, we report a black Nigerian male with GIST, who developed hypopigmentation of distal parts of digits, as well as generalized lightening of skin on the body three months after receiving imatinib mesylate. We believe that this is the first case of hypopigmentation reported in a black patient with GIST.
甲磺酸伊马替尼（STI 571，格列卫）是一种有效的bcr-abl酪氨酸激酶抑制剂。它还能抑制c-kit酪氨酸激酶。甲磺酸伊马替尼在治疗慢性粒细胞白血病（CML）和胃肠道间质瘤（GIST）方面具有活性。一些权威机构认为它是新诊断的CML以及慢性期无相关匹配供体患者的标准治疗药物。c-kit及其配体干细胞因子调节黑素细胞的发育和存活。最近有报道称接受甲磺酸伊马替尼治疗CML的患者出现色素减退。在本文中，我们报告了一名患有GIST的尼日利亚黑人男性，在接受甲磺酸伊马替尼三个月后，其手指远端出现色素减退，身体皮肤也出现全身性变浅。我们认为这是首例报道的患有GIST的黑人患者出现色素减退的病例。
